By activating GLP-1 receptors in the brain, pancreas, and digestive tract, semaglutide reduces appetite, slows gastric emptying, and improves insulin sensitivity
HealthVerity Marketplace offers a privacy-protected, interoperable platform that makes these insights accessible at scale
Nature Chemistry 3:509524 Williams DM, et al (2024) Real-World clinical experience of oral semaglutide in a secondary diabetes clinic in the UK: a retrospective observational study
Observed reductions in BP after 68 weeks of CagriSema treatment versus placebo were greater than those previously observed over the same time frame for semaglutide 2.4 mg in participants with overweight or obesity in the Semaglutide Treatment Effect in People with Obesity (STEP) 1, STEP 3, and STEP 4 trials, with an overall reduction in SBP versus placebo across the 3 trials of 5.0 (95% CI, 5.9 to 4.1) mm Hg
Fewer people had to stop the medication because of these problems